X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/pharma/novartis-dials-2024-sales-outlook-preps-key-expansions-3-cancer-drugs
https://endpts.com/novartis-plots-new-pluvicto-filing-timeline-after-waiting-for-overall-survival-results/
https://www.fiercepharma.com/manufacturing/novartis-expands-pluvicto-manufacturing-footprint-fda-blessing-indianapolis
https://endpts.com/novartis-on-track-to-complete-restructuring-post-sandoz-spin-pushes-back-pluvicto-filing/
https://www.prnewswire.com/news-releases/novartis-pluvicto-shows-clinically-meaningful-and-highly-statistically-significant-rpfs-benefit-in-patients-with-psma-positive-metastatic-castration-resistant-prostate-cancer-in-the-pre-taxane-setting-301964619.html
https://www.ema.europa.eu/en/documents/overview/pluvicto-epar-medicine-overview_en.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-23-2023-6184.pdf
https://www.onclive.com/view/olaparib-bolsters-lutetium-lu-177-vipivotide-tetraxetan-activity-in-mcrpc
https://www.fiercepharma.com/manufacturing/relief-pluvicto-shortage-fda-quickly-clears-novartis-radiotherapy-manufacturing
https://www.fiercepharma.com/manufacturing/novartis-halts-pluvicto-new-patient-starts-struggles-radiotherapy-supply-amid
https://www.ema.europa.eu/en/documents/overview/pluvicto-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-pluvicto-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer
https://www.globenewswire.com/news-release/2022/12/05/2567028/0/en/Novartis-Pluvicto-shows-statistically-significant-and-clinically-meaningful-radiographic-progression-free-survival-benefit-in-patients-with-PSMA-positive-metastatic-castration-resi.html
https://www.globenewswire.com/news-release/2022/10/14/2534539/0/en/Novartis-receives-positive-CHMP-opinion-for-Pluvicto-for-patients-with-progressive-PSMA-positive-metastatic-castration-resistant-prostate-cancer.html
https://www.europeanpharmaceuticalreview.com/news/173672/mhra-approves-pluvicto-and-locametz-for-prostate-cancer/
https://pharmaphorum.com/news/novartis-pluvicto-gets-first-european-approval-in-gb/
http://investor.endocyte.com/news-releases/news-release-details/endocyte-and-itm-announce-long-term-supply-agreement-no-carrier
http://investor.endocyte.com/news-releases/news-release-details/image-following-treatment-177lu-psma-617-selected-society
http://investor.endocyte.com/news-releases/news-release-details/endocyte-join-russell-3000r-index
http://investor.endocyte.com/news-releases/news-release-details/endocyte-announces-presentations-psma-617-2018-society-nuclear
http://investor.endocyte.com/news-releases/news-release-details/endocyte-announces-enrollment-first-patient-phase-3-vision-trial
http://investor.endocyte.com/news-releases/news-release-details/endocyte-announces-presentation-phase-2-data-investigator
http://investor.endocyte.com/news-releases/news-release-details/endocyte-announces-pricing-public-offering-common-stock
Market Place
Share 
